替格瑞洛在急性冠状动脉综合征中的研究进展

Research Progress of Ticagrelor in Acute Coronary Syndrome

替格瑞洛是一种直接作用、可逆结合的新型强效P2Y12受体拮抗剂,其适应证为急性冠状动脉综合征(ACS)。ACS是以冠状动脉粥样硬化斑块破裂或侵袭,继发完全或不完全闭塞性血栓形成为病理基础的一组临床综合征,是冠心病的一种严重类型。双联抗血小板治疗,即阿司匹林联合P2Y12受体拮抗剂是ACS和(或)经皮冠状动脉介入(PCI)治疗患者的标准治疗方法,对接受药物治疗和PCI的患者,规范实施双联抗血小板治疗是改善预后、降低病死率的关键。未来,临床应选择更有效、更安全的抗血小板药物。

Ticagrelor is a new type of powerful P2Y12 receptor antagonist with direct action and reversible combination.Its indication is acute coronary syndrome(ACS).ACS is a group of clinical syndromes based on the rupture or invasion of coronary atherosclerotic plaques and secondary complete or incomplete occlusive thrombosis.It is a serious type of coronary heart disease.Dual antiplatelet therapy,i.e.aspirin plus P2Y12 receptor antagonist is routinely preccribed to ACS and/or percutaneous coronary intervention(PCI)patients on standard treatment.For patients receiving medication and PCI,standardizing the implementation of dual antiplatelet therapy to improve the prognosis,is the key to reduce the fatility.In the future,more effective and safer antiplatelet drugs should be chosen in clinical.